RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
Cited by 50
Related Papers
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
|Frontiers in Immunology|2021|163
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
|Theranostics|2019|70
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
|BMC Cancer|2014|54
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
|EClinicalMedicine|2023|26
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
|British Journal of Cancer|2025|7